Abstract
The diagnosis of ischemic heart disease СOVID-19 has caused obvious difficulties, because the lack of blood circulation can take the clinical picture of many specific diseases and it is impossible to update it in time. fatigue, tachycardia, tachypnea, wheezing in the lungs during auscultation, accumulation of fluid in the pleural cavity, management may occur. People with diseases of the cardiovascular system are the main risk group of getting infected with СOVID-19. Patients with hypertension (HK), CKD, and diabetes mellitus (DM) are more likely to suffer from COVID-19, which in turn complicates CKD and, in some cases, results in death. This is related to the systemic effect of the coronavirus infection СOVID-19 on the body. Thus, due to the fact that the damage to the cardiovascular system during the infection with KOV-19 has not been thoroughly studied pathogenetically and the effectiveness of treatment against it is low, this disease worsens in patients with diseases of the cardiovascular system, causing the development of various complications of these diseases and even the development of death. due to its possibility, it has become an actual problem of modern-day cardiology. Z. Jing and co-authors (2020) recommended urgent in-hospital reperfusion with thrombolytic therapy when ST-segment elevation ACS is detected in individuals with confirmed or suspected COVID-19. Z. Jing and co-authors (2020) recommended urgent in-hospital reperfusion with thrombolytic therapy when ST-segment elevation ACS is detected in individuals with confirmed or suspected COVID-19. But E. Mahmud and co-authors opposed this idea. First, in such cases, performing thrombolysis is not justified and may introduce additional risks. Second, thrombolysis helps only in 50-60% of cases, and after ineffective thrombolysis, percutaneous coronary intervention is still necessary.